In the original article, there was a mistake in Table 2 as published. The row headers of Table 2 in the article are missing. The corrected Table 2 appears below.
Table 2
| References | Study | Participants | Number | Intervention | Duration | Primary Outcomes |
|---|---|---|---|---|---|---|
| Hara et al., 2014 | Randomized double-blind placebo-controlled trial | Country : Japan Site: multicenter | Total: 252 IGU+MTX group:165 (PLA/IGU)+MTX group: (Weeks 1-28):88 (Weeks28–52):68 | IGU+MTX group: IGU 25mg Bid,MTX 6 or 8 mg Qw and folic acid 5mg Qw(0-52 weeks). (PLA/IGU)+MTX group: Pla tablets(1-28 weeks); MTX 6 or 8mg Qw and folic acid 5 mg QW(1-52 weeks);IGU 25mg Qd(28-32 weeks),25mg Bid (32-52 weeks). | 52 weeks | ACR20 at week 52:IGU+MTX group was similar to that at week 24 (69.5%).(PLA/IGU)+MTX group, the switch to IGU treatment signficantly improved from 30.7% at week 24 to 72.1% at week 52. ACR50, ACR70 at week 52: IGU+MTX group was significantly improved compared with the values at week 24. |
| Ishiguro et al., 2013 | Randomized double-blind placebo-controlled trial | Country : Japan Site:multicenter | Total: 252 IGU group:164 placebo group:88 | IGU group:164 IGU 25mg Qd (0-4 weeks) 25mg Bid (4-24 weeks). MTX 6 or 8mg Qw, folic acid 5mg Qw. placebo group: MTX 6 or 8mg Qw and folic acid 5mg Qw,and placebo tablets | 24 weeks | ACR20 at week 24 was 69.5% in the IGU group compared with 30.7% in the placebo group (P < 0.001). Significant improvements in the ACR50, ACR70. |
| Xia et al., 2016 | Prospective trial | Country : Japan Site: Single-center | Total: 131 MTX+IGU group:44 IGU group:38 MTX group:49 | IGU group:25mg Bid(0-24 weeks) MTX group:10mg Qw (0-24 weeks) MTX+IGU group: IGU 25mg Bid (0-24 weeks).MTX 10mg Qw (0-24 weeks) | 24 weeks | ACR 20 and ACR 50 at 24 weeks: combination of IGU with MTX was superior to IGU or MTX monotherapy. |
| Duan et al., 2015 | Randomized controlled trial | Country : China Site : Single-center | Total: 60 MTX+ IGU group:30 MTX group:30 | MTX+ IGU group: IGU 25mg Bid (0-24 weeks).MTX 10mg Qw (0-4 weeks),12.5mg Qw (4-24 weeks) MTX group: 10mg Qw (0-4 weeks),12.5mg Qw (4-24 weeks) | 24 weeks | ACR50 at 24 weeks:MTX+T-614 group showed statistically significant differences comparing with the MTX group (P < 0.05). |
| Yoshikawa et al., 2018 | Retrospective study | Country : Japan Site: Single-center | Total: 41 patients who showed an inadequate response to biological DMARDs | IGU 25mg Qd (0-4 weeks), then increased to 25mg Bid based on the physician’s discretion. | 24 weeks | remission can be achieved by IGU addon in RA patients responding partially to 24-week or longer administration of bDMARD |
| Zheng et al., 2018 | Retrospective study | Country : China Site : Single-center | Total: 23 patients who showed an inadequate response to MTX–CsA–HCQ– prednisone | MTX:12.5mg Qw HCQ:0.1mg Bid CsA:50mg Bid Prednisone:7.5mg Qd IGU: 25mg Bid | 24 weeks | After 24 weeks:the RA patients showed a significant improvement in mean DAS28 score from baseline. 18 (78%), 15 (65%), and 12 (50%) patients, respectively, met the ACR20, ACR50, and ACR70 response criteria. |
| Ebina et al., 2019 | Retrospective study | Country: Japan Site: multicenter | Total: 31 patients who showed an inadequate response to TCZ | TCZ 162mg Q2w or 8 mg/kg Qm;IGU 25 mg Qd,then increased to 25mg Bid depending on physician’s decision. | 24 weeks | Using the EULAR criteria, 64.5% achieved a moderate response, and 51.6% achieved ACR 20 at 24 weeks |
| Suto et al., 2019 | Retrospective study | Country : Japan Site:multicenter | Total: 69 IGU group:28 MTX+IGU:28 bDMARDs+IGU:13 | IGU group:IGU 25mg Qd (0-4 weeks), then increased to 25mg Bid based on the physician’s discretion. MTX+IGU group: MTX was 8.5 ± 3.4 mg/week bDMARDs+IGU group: IFX/ETN/ADA/TCZ/ABT/GLM(n=1/4/3/1/2/2) | 36 months | The survival rate of IGU therapy at 3 years was 40.6%. The disease activity was significantly decreased in the IGU group and MTX plus IGU group compared with the baseline. |
Characteristics of the clinical trials of iguratimod in combination for RA.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
References
1
DuanX. W.ZhangX. L.MaoS. Y.ShangJ. J.ShiX. D. (2015). Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin. Rheumatol.34 (9), 1513–1519. doi: 10.1007/s10067-015-2999-6
2
EbinaK.MiyamaA.TsuboiH.KaneshiroS.NishikawaM.OwakiH.et al. (2019). The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod. Rheumatol.29 (4), 581–588. doi: 10.1080/14397595.2018.1486939
3
HaraM.IshiguroN.KatayamaK.KondoM.SumidaT.MimoriT.et al. (2014). Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol.24 (3), 410–418. doi: 10.3109/14397595.2013.843756
4
IshiguroN.YamamotoK.KatayamaK.KondoM.SumidaT.MimoriT.et al. (2013). Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol.23 (3), 430–439. doi: 10.1007/s10165-012-0724-8
5
SutoT.YonemotoY.OkamuraK.SakaneH.TakeuchiK.TamuraY.et al. (2019). The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Mod. Rheumatol.29 (5), 775–781. doi: 10.1080/14397595.2018.1510879
6
XiaZ.LyuJ.HouN.SongL.LiX.LiuH. (2016). Iguratimod in combination with methotrexate in active rheumatoid arthritis: Therapeutic effects. Z. Rheumatol.75 (8), 882–833. doi: 10.1007/s00393-015-1641-y
7
YoshikawaA.YoshidaS.KimuraY.TokaiN.FujikiY.KotaniT.et al. (2018). Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Mod. Rheumatol.28 (2), 227–234. doi: 10.1080/14397595.2017.1336865
8
ZhengN.GuoC.WuR. (2018). Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate– cyclosporin A–hydroxychloroquine–prednisone. Scandinavian. J. Rheumatol.47 (5), 422–424. doi: 10.1080/03009742.2017.1376109
Summary
Keywords
iguratimod, rheumatoid arthritis, NF-kappa B, randomized controlled trial, pharmacology
Citation
Xie S, Li S, Tian J and Li F (2020) Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape. Front. Pharmacol. 11:488. doi: 10.3389/fphar.2020.00488
Received
23 March 2020
Accepted
27 March 2020
Published
08 April 2020
Volume
11 - 2020
Edited and reviewed by
Gerard Bannenberg, GOED, United States
Updates
Copyright
© 2020 Xie, Li, Tian and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fen Li, Lifen0731@csu.edu.cn
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.